Below are the financial statements of Royalty Pharma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 | 2022 |
|---|---|---|---|
| Income and other revenues | — | — | — |
| Income from financial royalty assets | 2,149.42a | 2,197.75a | 2,125.1a |
| Other royalty income and revenues | 114.15a | 156.8a | 112.12a |
| Total income and other revenues | 2,263.58a | 2,354.55a | 2,237.22a |
| Operating expense | — | — | — |
| Provision for changes in expected cash flows from financial royalty assets | -732.46a | -560.66a | -904.24a |
| Research and development funding expense | -2a | -52a | -177.11a |
| Amortization of intangible assets | 0a | 0a | -5.67a |
| General and administrative expenses | -236.67a | -249.75a | -227.3a |
| Financial royalty asset impairment | 0a | 0a | -615.83a |
| Total operating expense, net | -971.13a | -862.4a | -1,930.15a |
| Operating income | 1,292.44a | 1,492.15a | 307.07a |
| Other (income)/expense | — | — | — |
| Equity in (earnings)/losses of equity method investees | -29.61a | -28.88a | 8.97a |
| Interest expense | -225.51a | -187.19a | -187.96a |
| Losses/(gains) on derivative financial instruments | 6a | 2.29a | -96.61a |
| (Gains)/losses on equity securities | -39.55a | -87.14a | 33.44a |
| (Gains)/losses on available for sale debt securities | -154.91a | -230.84a | 6.82a |
| Interest income | -47.34a | -72.29a | -78.34a |
| Other non-operating expenses, net | 1.53a | 21.74a | 14.76a |
| Total other (income)/expense, net | -38.37a | -207.94a | 77a |
| Consolidated net income before tax | 1,330.81a | 1,700.09a | 230.06a |
| Income tax expense | 0a | 0a | 0a |
| Consolidated net income | 1,330.81a | 1,700.09a | 230.06a |
| Net income attributable to non-controlling interests | 471.83a | 565.25a | 187.23a |
| Net income attributable to Royalty Pharma plc | 858.98a | 1,134.83a | 42.83a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.